GR2002 / Genrix Bio - LARVOL DELTA

Safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a novel anti-TSLP bispecific antibody (GR2002) in healthy Chinese adults: a randomized, placebo-controlled phase 1 trial. (PubMed, Eur J Pharm Sci) - "Single-dose subcutaneous administration of GR2002 demonstrated favorable safety and tolerability, linear PK, and low immunogenicity. These findings warrant the subsequent clinical development of STSA-1002."

Clinical • Journal • P1 data • PK/PD data • Infectious Disease • Respiratory Diseases • TSLP

Preclinical Development of GR2002, a Novel Anti-TSLP Bispecific Antibody With Potent TSLP Inhibitory Effects. (PubMed, Allergy) - No abstract available

Journal • Preclinical • Allergy • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

The Study of Single Dose Administration of GR2002 Injection in Chinese Health Volunteers (clinicaltrials.gov) - P1 | N=50 | Completed | Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Recruiting ➔ Completed

Trial completion • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

A Study to Evaluate the Safety and Efficacy of GR2002 Injection in Patients With Atopic Dermatitis. (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd.

New P1 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology